|
Primary malignant neoplasm of lung
|
|
0.070 |
GeneticVariation
|
BEFREE |
Adding mTOR and IGF1R inhibitors to ARS-1620 greatly improves its effectiveness on KRAS-G12C mutant lung cancer cells in vitro and in mouse models.
|
31534020 |
2019 |
|
Primary malignant neoplasm of lung
|
|
0.070 |
GeneticVariation
|
BEFREE |
Gene-expression profiles in lung cancer cell lines and surgically resected lung AC revealed that KRAS-G12C mutants had an epithelial to mesenchymal transition and a KRAS-independent phenotype.
|
25170638 |
2014 |
|
Primary malignant neoplasm of lung
|
|
0.070 |
GeneticVariation
|
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |
|
Primary malignant neoplasm of lung
|
|
0.070 |
GeneticVariation
|
BEFREE |
Although this mutation in KRAS accounts for 11% of all KRAS mutations in cancer, it is the most prominent KRAS mutant in lung cancer suggesting that G12C-specific inhibitors may provide a new approach for treating the subset of lung cancer patients harboring this mutant allele.
|
30366101 |
2019 |
|
Primary malignant neoplasm of lung
|
|
0.070 |
GeneticVariation
|
BEFREE |
Next generation sequencing performed on the Ion Torrent platforms by the Ion Ampliseq Colon and Lung Cancer panel showed a similar genomic profile in both neoplastic sites with a concurrent KRAS G12C mutation.
|
25900221 |
2015 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Our result highlighted that the gross metabolic changes observed in G12C KRAS mutant cells growing in culture were also maintained in the derived xenograft model, suggesting that a simple in vitro cell model can give important insights into the metabolic alterations induced by cancer.
|
27329432 |
2016 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Additionally, the specific p.G12R NRAS mutation in this case is a common somatic mutation in cancer cells, and analysis of previously reported NRAS-RASopathy cases suggests that mutations at traditionally oncogenic codons are associated with elevated cancer risk not present with mutations at other sites.
|
31697451 |
2020 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
GeLC-MRM detected KRAS mutant variants (G12D, G13D, G12V, G12S) in a panel of cancer cell lines.
|
22671702 |
2012 |
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
G12D, G12V, G12C) of V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras), the most promising drug target in cancer therapy, are major growth drivers in various cancers.
|
28153726 |
2017 |
|
Primary cholangiocarcinoma of intrahepatic biliary tract
|
|
0.010 |
GeneticVariation
|
BEFREE |
Molecular studies showed one mucinous iCC with KRAS G12C mutation and no BRAF or IDH1/2 mutations.
|
29698701 |
2018 |
|
Poorly differentiated carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
NGS revealed a BRAF p.K601E mutation in both the clear cell papillary carcinoma and poorly differentiated carcinoma and a KRAS p.G12R mutation in the papillary carcinoma, follicular variant.
|
27387987 |
2017 |
|
polyps
|
|
0.020 |
GeneticVariation
|
BEFREE |
There was a strong association between germinal MUTYH mutation and KRAS Gly12Cys somatic mutation in polyps.
|
24470512 |
2014 |
|
polyps
|
|
0.020 |
GeneticVariation
|
BEFREE |
The analysis of MUTYH-associated polyposis cases of the EPIPOLIP cohort confirms the importance of including serrated polyps in the diagnostic work-up of patients with oligopolyposis, suggests a role for screening polyps for the somatic c.34G>T KRAS mutation, and allows the implementation of a genetic testing strategy based on population data.
|
24486588 |
2014 |
|
Papillary carcinoma, clear cell
|
|
0.010 |
GeneticVariation
|
BEFREE |
NGS revealed a BRAF p.K601E mutation in both the clear cell papillary carcinoma and poorly differentiated carcinoma and a KRAS p.G12R mutation in the papillary carcinoma, follicular variant.
|
27387987 |
2017 |
|
Papillary and follicular adenocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
NGS revealed a BRAF p.K601E mutation in both the clear cell papillary carcinoma and poorly differentiated carcinoma and a KRAS p.G12R mutation in the papillary carcinoma, follicular variant.
|
27387987 |
2017 |
|
Pancreatic carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
This study suggests that the combination of RAF and CDK4/6 inhibitors might be a novel treatment strategy for KRAS G12R mutant pancreatic cancer.
|
30271501 |
2018 |
|
Pancreatic carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM).
|
29262834 |
2017 |
|
Pancreatic carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Presence of the KRAS G12C mutation had 96% specificity and positive predictive value for lung adenocarcinoma, whereas G12R was 99% specific for pancreatic cancer with a positive predictive value of 86%.
|
23887294 |
2014 |
|
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
|
21975775 |
2011 |
|
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
|
19018267 |
2008 |
|
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
|
21975775 |
2011 |
|
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
|
19018267 |
2008 |
|
Noonan Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
We have observed unusual transverse distal phalangeal creases in two patients, one with Costello syndrome (G12S mutation in the HRAS gene) and one with cardio-facio-cutaneous (CFC) syndrome or possibly Noonan syndrome (Q22E mutation in the KRAS gene).
|
17324647 |
2007 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Recently, G12C KRAS mutation in isogenic NSCLC cell line has been shown to be a key player in promoting metabolic rewiring mainly through the regulation of glutamine metabolism to fuel growth and proliferation.
|
27329432 |
2016 |
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Isogenic NSCLC cell clones expressing wild-type (WT) and mutated (G12C) KRAS were used to determine the response to BEZ235 and BKM120.
|
27283493 |
2016 |